Last edition
News about "Ropanicant"
Suven Life Sciences reported positive phase 2b results for Ropanicant in Major Depressive Disorder (MDD), achieving significant improvements in depression symptoms versus placebo. The treatment showed favorable safety and tolerability, with no withdrawal symptoms or dissociation, supporting advancement into a global phase 3 study.
Ropanicant | 17/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members